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a b s t r a c t
Background: Recent evidence suggests that two doses of HPV vaccinesmay be as protective as three doses
in the short-term. We estimated the incremental cost-effectiveness of two- and three-dose schedules of
girls-only and girls & boys HPV vaccination programmes in Canada.
Methods: We used HPV-ADVISE, an individual-based transmission-dynamic model of multi-type HPV
infection anddiseases (anogenitalwarts, and cancers of the cervix, vulva, vagina, anus, penis andorophar-
ynx). We conducted the analysis from the health payer perspective, with a 70-year time horizon and 3%
discount rate, and performed extensive sensitivity analyses, including duration of vaccine protection and
vaccine cost.
Findings: Assuming 80% coverage and a vaccine cost per dose of $85, two-dose girls-only vaccination (vs.
no vaccination) produced cost/quality-adjusted life-year (QALY)-gained varying between $7900–24,300.
The incremental cost-effectiveness ratio of giving the third dose to girls (vs. two doses) was below
$40,000/QALY-gained when: (i) three doses provide longer protection than two doses and (ii) two-dose
protection was shorter than 30 years. Vaccinating boys (with two or three doses) was not cost-effective
(vs. girls-only vaccination) under most scenarios investigated.
Interpretation:Two-doseHPVvaccination is likely tobe cost-effective if its durationofprotection is at least
10 years. A third dose of HPV vaccine is unlikely to be cost-effective if two-dose duration of protection is
longer than 30 years. Finally, two-dose girls & boys HPV vaccination is unlikely to be cost-effective unless
the cost per dose for boys is substantially lower than the cost for girls.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The majority of high income countries have introduced
three-dose routine human papillomavirus (HPV) vaccination
programmes [1]. Although most countries are vaccinating
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girls/women, only the US, Australia and one Canadian province
(Prince Edward Island) have included boys in their routine HPV
vaccination programmes. The most commonly used HPV vaccine
in high income countries (including Canada, the UK, the US and
Australia) is thequadrivalent [1],whichprotects againstHPV-16/18
(responsible for more than 70% of cervical cancers [2] and associ-
ated with other anogenital [3,4] and head and neck cancers [5])
and HPV-6/11 (associated with more than 85% of anogenital warts
[6]). Although vaccinating girls against HPV is expected to dramat-
ically reduce the burden of HPV-associated diseases [7,8] and to be
highly cost-effective [9–11], it nevertheless imposes an important
ﬁnancial strain on immunisation budgets. In Canada, HPV vaccine
http://dx.doi.org/10.1016/j.vaccine.2014.07.099
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represents 40%of the total cost to fully immunise a girl from infancy
to adolescence (Dr. Bruno Turmel, Quebec Ministry of Health and
Social Services, Personal communication) [12]. Decision-makers
may thus be interested in the possibility of reducing doses of HPV
vaccine to invest the funds on improving coverage to underserved
populations, male HPV vaccination or other immunisation pro-
grammes.
Recent evidence suggests that two doses of HPV vaccine may
be as protective as three doses in the short-term. A nested nonran-
domisedanalysiswithinaphase III randomisedclinical trial inCosta
Rica suggested that two doses of HPV vaccine has similar high efﬁ-
cacy against vaccine-type persistent infections as three doses, four
years after vaccination [13]. More recently, a phase III randomised
trial examined the immunogenicity of two doses in girls 9–13 years
compared to three doses in girls 9–13 years and three doses among
young women 16–26 years. Results from the study showed that
antibody responses for the vaccine-types among girls (9–13 years)
who received two doses were noninferior to those among young
women (16–26 years) who received three doses, over a period of
three years after the last vaccine dose [14]. However, antibody
responses to HPV-18 at two years and HPV-6 at three years were
signiﬁcantly lower for girls (9–13 years) who received two doses
vs. girls (9–13 years) who received three doses. Because noninferi-
ority did not persist over time for all vaccine types when directly
comparing the two groups of girls aged 9–13 years, the authors of
the clinical trial, and those from the accompanying editorial [15],
concluded that more data on duration of protection is required
before reduced-dose schedules are recommended or implemented.
However, such information will not be available for several years.
Furthermore, data on duration of protection is not typically avail-
ablewhennewvaccines are introduced (e.g., durationof three-dose
HPV vaccine protection is still unknown).
Mathematical models are particularly well-suited and increas-
ingly used to provide timely evidence to inform immunisation
policy-decisions when empirical data is scarce or incomplete
[16], as they provide a formal framework to synthesise infor-
mation from various sources (e.g., clinical trials, epidemiological
studies) to make predictions about the population-level effective-
ness and cost-effectiveness for different what-if scenarios (e.g.,
vaccinating girls-only or girls and boys, different durations of vac-
cine protection). To our knowledge, no model has examined the
cost-effectivenessof two-doseHPVvaccinationor theoptimal com-
bination of number of HPV vaccine doses and vaccination strategy
(e.g., girls-only vs. girls and boys). The objectives of this study
were to: (i) estimate the incremental cost-effectiveness of two-
and three-dose schedules of girls-only and girls & boys HPV vac-
cination programmes, and (ii) identify the duration of two- and
three-dose HPV vaccine protection necessary for a third dose to be
cost-effective.
2. Methods
2.1. Study design & economic analysis
HPV-ADVISE, an individual-based transmission-dynamicmodel
of multi-type HPV infection and disease, was used for model pre-
dictions [8,17,18]. Cost–utility analysis (cost/QALY-gained) was
chosen as the analytic technique and the analysis was performed
using the healthcare payer perspective. Costs were inﬂated to
2010 Canadian dollars using the Canadian Consumer Price Index
for Health. Costs and outcomes were discounted at 3%/year. A
70-year time-horizon was chosen for our reference-case (average
life-expectancy of the ﬁrst cohort of vaccinated girls). Sensitiv-
ity analysis on the discount rate and time-horizon was conducted
as per good-modelling practice [19]. As suggested by WHO
guidelines [20,21], the Canadian per capita GDP was used as the
cost-effectiveness threshold. Hence, vaccination strategies below
$40,000/QALY-gained were considered cost-effective.
2.2. Strategies investigated
The incremental costs, beneﬁts, and cost-effectiveness ratios of
the following HPV vaccination strategies were examined:
(1) Two-dose girls-only vs. no vaccination
(2) Three-dose girls-only vs. two-dose girls-only vaccination
(3) Two-dose girls & boys vs. two-dose girls-only vaccination
(4) Three-dose girls & boys vs. three-dose girls-only or two-dose
girls & boys vaccination
In our base-case scenario, routine vaccination is given at 9 years
of age. Of note, all vaccination scenarios include a ﬁve-year three-
dose catch-up campaign for 14-year-old girls. Vaccination coverage
was 80%, similar to coverage in UK (79–91%) [22] and Australia
(64–80%) [23]. Vaccination coverage, ages at vaccination, vaccina-
tion schedules and the catch-up campaign are based on the current
girls-only HPV vaccination programme in Quebec, Canada [24].
However, vaccination coverage and the three-dose schedule were
varied in sensitivity analysis. HPV vaccination was introduced ﬁve
years ago in Canada (in 2008) and in many developed countries.
Hence, all changes in vaccination strategies are modelled to occur
during the 6th year of the programme. See Supplementary Fig. 1
for a detailed description of the vaccination strategies examined in
our base-case scenario.
2.3. Model structure
The model structure of HPV-ADVISE is described in great detail
elsewhere [8,17,18]. Brieﬂy, individuals in themodel are attributed
four different risk factors for HPV infection and/or disease: gen-
der, sexual orientation, sexual activity level and screening level.
Eighteen HPV-types are modelled individually (including HPV-
16/18/6/11/31/33/45/52/58). The diseasesmodelled are anogenital
warts and cancers of the cervix, vulva, vagina, anus, penis, and
oropharynx. Cytologywasused for cervical cancer screening,which
reﬂects current practice in Canada. Screening rates are a function
of a woman’s screening behaviour level, previous screening test
results, and age. Finally, direct medical costs and Quality-Adjusted
Life-Year (QALY) weights were attributed to outcomes (e.g., diag-
nosed lesions, cancer) over time.
2.4. Parameter values
Sexual behaviour, natural history and cervical screening
parameters were identiﬁed by ﬁtting the model to 782 sex-
ual behaviour, HPV epidemiology and screening data target
points, taken from the literature, population-based datasets,
and original studies [25–37] (see Van de Velde et al. [8]
and www.marc-brisson.net/HPVadviseCEA.pdf). Vaccine-type and
cross-protective efﬁcacy estimates were based on a recent meta-
analysis [38] (see Supplementary Table 1), and assumed to be
equal for two- and three-dose schedules based on the short-
term results of the noninferiority trial [13]. Type-speciﬁc efﬁcacy
and cross-protection were assumed to be equal for cervical and
non-cervical sites. The duration of vaccine-type efﬁcacy and cross-
protection remains uncertain for two and three doses. Currently,
clinical data show no evidence of waning for three-dose vaccine-
type efﬁcacy after 9.5 years [39] and potential limited duration
of cross-protective efﬁcacy [38]. Given such uncertainty, we var-
ied the average duration of vaccine-type efﬁcacy for three doses
between 20 years and lifelong, and for two doses between 10 years
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and lifelong. It is important to note that duration of protection is
calculated from the time of the ﬁrst dose. Furthermore, in sce-
narios with limited vaccine duration, each vaccinated individual
is given a speciﬁc duration of protection sampled from a normal
distribution (=varied;  =5 years) [17], as not all individuals will
lose protection at the same time after vaccination. In the base-case
scenarios, cross-protection was assumed to last 10 years. A sce-
nariowas also examinedwhere two-dose schedules do not provide
cross-protection. TheHPV vaccine cost per dose including adminis-
tration was $85. QALY-weights and unit costs were taken from the
literature [25,26,40–48] (see Supplementary Table 2).
2.5. Sensitivity & uncertainty analyses
In univariate sensitivity analysis, vaccine efﬁcacy (for cervical
and non-cervical sites), duration of protection, percent of anogeni-
tal warts due to HPV-6/11, proportion of the male population that
are men-who-have-sex-with-men (MSM), relative risk of disease
in MSM vs. heterosexual men, costs and QALY-weights were varied
between their minimum and maximum values found in the litera-
ture (Supplementary Tables 1 and 2). Finally, favourable scenarios
for vaccination of boys were examined in multivariate sensitivity
analysis. Variability of model predictions due to natural history
parameters is presented as the median, and ﬁrst and third quar-
tiles of simulation results, referred to as the interquartile ranges
(IQR).
3. Results
3.1. Population-level impact and costs
Table 1 shows the potential population-level effectiveness of
two-and three-dose schedules assumingdifferentdurationsofpro-
tection (see Supplementary Fig. 2 for post-vaccination dynamics).
Under our base-case (coverage=80%, vaccine-type efﬁcacy=95%)
and assuming two-dose vaccine duration of protection is 10 years,
two-dose girls-only vaccination is predicted to prevent a cumulative
13% of HPV-related cancer cases (12% anogenital warts consulta-
tions) over 70 years. Over the same time-horizon, giving a third
dose in a girls-only vaccination programme prevents between 13
and 15% extra HPV-related cancer cases, if the duration of pro-
tection from three doses is between 25 years and lifelong. The
equivalent expanded reductions in anogenital warts consultations
are between 54 and 60%. Switching to a two-dose girls & boys strat-
egy would prevent an extra 3% HPV-related cancer cases and 9%
anogenital warts consultations compared to a two-dose girls-only
vaccination policy. However, when assuming the duration of pro-
tection of two doses is 20 or 30 years, the incremental beneﬁts of
giving a third dose to girls-onlyor switching to a two-dose girls&boys
strategy are predicted to be relatively small (e.g., between 2 and 6%
extra HPV-related cancer cases prevented; Table 1). Of note, the
additional beneﬁts provided by a third dose to girls-only are mostly
among females whilst the majority of beneﬁts of switching to a
two-dose girls & boys strategy are among MSM.
Fig. 1 shows the discounted QALYs-gained and cost offsets for
girls-only and girls & boys vaccination programmes using two- and
three-dose schedules. The incremental QALYs-saved and cost off-
sets by giving a third dose to girls-only are relatively small when
assuming that two-dose protection is 20 years or more, but would
increase the overall cost of the programme by almost 30%. Unless
two and three doses provide equal duration of protection, switch-
ing to a two-dose girls & boys vaccination strategy is predicted
to provide similar or lower incremental discounted QALYs-gained
and cost-offsets than adding a third dose to girls-only. However,
because it requires providing twice the additional number of vac-
cine doses, giving two doses to boys would be more than twice the
cost of adding a third dose to girls (incremental cost of a third dose
girls=$109 million vs. two-dose boys=$256 million over 70 years of
vaccination in a population of 10 million, results not shown).
3.2. Cost-effectiveness
Compared to no vaccination, all two- and three-dose girls-only
and girls & boys HPV vaccination strategies investigated produce
cost-effectiveness ratios below the $40,000/QALY-gained cost-
effectiveness threshold (Fig. 2, and see Supplementary Table 3 for
detailed results).
In the base-case, two-dose girls-only vaccination (vs. no
vaccination) consistently produces the lowest incremental cost-
effectiveness ratio with cost/QALY-gained varying between $7900
[IQR: 7000;9700] and $10,400 [IQR: 8800;13,400] (Fig. 2b–f). The
only exception iswhen two-dose duration of protection is assumed
to be 10 years (Fig. 2a). In the sensitivity analysis, two-dose
girls-only vaccination cost-effectiveness ratios remained below
$40,000/QALY-gained (Fig. 3a). The maximum cost per dose for
two-dose girls-only vaccination to remain cost-effective (vs. no vac-
cination) is predicted to be $128, $218 and $252 assuming two-dose
vaccine protection lasts 10, 20 and 30 years, respectively (see Sup-
plementary Fig. 4 and Table 4).
The incremental cost-effectiveness ratio of giving the third dose
of vaccine to girls (i.e., of three-dose girls-only vs. two-dose girls-only)
is estimated to be below $40,000/QALY-gained if: (i) three doses
provide longer protection than two doses (i.e., more than 5 years),
and ii) two-dose protection is less than 30 years (Figs. 2c, d and 3b).
Under most scenarios, two-dose girls & boys vaccination (vs.
two-dose girls-only) provides fewer or similar QALYs-gained and is
more expensive than three-dose girls-only vaccination (i.e., is dom-
inated; Figs. 2a, c–f and 3b). The only exceptions are: (i) if the third
dose provides little or no additional protection to two doses, (ii)
when extreme scenarios for burden of HPV-disease among MSM
are assumed (e.g., 7% males are MSM, the relative risk of disease
among MSM vs. male heterosexuals is 17, and girls-only vaccina-
tion is assumed to have no effect on HPV-related disease incidence
in MSM) or (iii) when vaccine cost for boys is 10–40% of the cost for
girls (Fig. 3b, Supplementary Fig. 3).
Finally, the incremental cost-effectiveness ratio of three-dose
girls & boys vaccination (vs. three-dose girls-only) is greater than
$100,000/QALY-gained under all base-case scenarios andmost sce-
narios investigated in sensitivity analysis (Figs. 2 and 3c). In the
sensitivity analysis, three-dose girls & boys vaccination is estimated
to be less than $40,000/QALY-gained if the cost per dose for girls
and boys is substantially reduced (Supplementary Fig. 4c).
4. Discussion
Our modelling analysis suggests that two-dose girls-only vacci-
nation (compared to no vaccination) is likely to be cost-effective if
vaccine protection is longer than 10 years. Furthermore, two-dose
girls & boys is likely to provide similar or less QALYs-gained and to
be more expensive than three-dose girls-only strategy, unless the
third dose gives no added value or the price for boys is substan-
tially less than the price for girls. Hence, the key question is: how
long does two-dose protection have to be in order for the third
dose to be cost-ineffective among girls? Our results suggest this
threshold duration of protection for two doses is about 30 years.
Hence, if two doses protect for more than 30 years, then the third
dose will have to be priced substantially below $85 to be cost-
effective. Finally, three-dose girls & boys HPV vaccination is unlikely
to be cost-effective compared to three-dose girls-only vaccination,
as shown by most modelling studies, unless the cost of the vaccine
is substantially reduced [49–54].
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Table 1
Health outcomes saved over 70 years after the start of HPV vaccination under base-case assumptionsa (undiscounted; population=10 million).
2-Dose
duration=10 years
2-Dose
duration=20 years
2-Dose
duration=30 years
Cumulative
reduction (%)
Additional cumulative reductionb
(additional % cumulative reduction)c
Cumulative
reduction (%)
Additional cumulative reductionb
(additional % cumulative reduction)c
Cumulative
reduction (%)
Additional cumulative reductionb
(additional % cumulative reduction)c
Strategy 2-dose
Girls only
3-dose
Girls only
3-dose
Girls only
3-dose
Girls only
2-dose
Girls &
boys
2-dose
Girls only
3-dose
Girls only
3-dose
Girls only
3-dose
Girls only
2-dose
Girls &
boys
2-dose
Girls only
3-dose
Girls only
3-dose
Girls only
2-dose
Girls &
boys
Duration
(vaccine types)
10 yearsd 25 yearsd 35 yearsd Lifee 10 yearsd 20 yearsd 25 yearsd 35 yearsd Lifee 20 yearsd 30 yearsd 35 yearsd Lifee 30 yearsd
AGW
consultations
111,066
(11·6)
527,033
(53·9)
568,531
(57·0)
582,422
(60·0)
83,470
(8·6)
550,743
(57·5)
83,710
(8·7)
131,750
(13·7)
133,491
(13·9)
124,531
(13·0)
685,187
(71·4)
1414
(0·1)
776
(0·1)
49,596
(5·1)
Diagnosed
CIN2/3
47,140
(15·4)
89,502
(25·9)
121,485
(32·8)
163,260
(42·0)
13,076
(3·8)
111,443
(32·6)
30,360
(8·2)
52,677
(14·9)
85,107
(23·2)
10,751
(2·8)
144,149
(42·0)
17,704
(5·1)
50,134
(13·3)
12,096
(3·6)
Cancersf
Cervix 4606
(16·4)
4116
(18·2)
4617
(20·1)
5195
(22·5)
832
(2·9)
7266
(29·3)
1155
(4·8)
1696
(6·1)
2251
(8·6)
558
(2·0)
8261
(34·5)
596
(2·2)
1175
(4·5)
421
(1·6)
Anus 448
(10·2)
787
(9·2)
880
(10·3)
919
(10·8)
370
(4·4)
1444
(17·0)
193
(2·3)
281
(3·3)
328
(3·9)
443
(5·2)
1633
(19·3)
87
(1·0)
137
(1·6)
445
(5·2)
Oropharynx 847
(11·2)
1504
(10·3)
1657
(11·3)
1711
(11·7)
577
(3·9)
2736
(18·6)
334
(2·3)
485
(3·3)
541
(3·7)
568
(3·9)
3080
(21·0)
150
(1·0)
209
(1·4)
516
(3·5)
Vulva, vagina
and penile
457
(9·6)
655
(7·1)
684
(7·5)
717
(7·7)
121
(1·4)
1392
(15·0)
162
(1·7)
193
(2·1)
229
(2·5)
106
(1·1)
1528
(16·5)
58
(0·6)
95
(1·4)
92
(1·0)
All cancersg 7961
(13·1)
7191
(12·9)
7890
(14·4)
8576
(15·3)
1954
(3·3)
12,807
(22·3)
1879
(3·2)
2747
(4·3)
3387
(5·6)
1667
(2·8)
14,556
(25·4)
899
(1·5)
1597
(2·7)
1509
(2·6)
AGW: anogenital warts; CIN2/3: cervical intraepithelial neoplasia of grade 2 or 3.
a Base-case: vaccination coverage=80%, vaccine-type efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1.
b Cumulative reduction: median reduction in the cumulative incidence vs. 2-dose girls-only strategy over 70 years (each parameter set was run 50 times).
c Median of percentage differences compared to 2-dose girls-only. Note: We estimate the median of the differences for each simulation not the difference of medians.
d Duration of cross-protection=10 years.
e Duration of cross-protection= lifelong.
f HPV positive cancers only.
g All cancers: median of totals. Note: We estimate the median of the sums of additional cancer cases prevented for each simulation not the sum of medians.
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Fig. 1. Discounted QALYs-gained and cost offsets over 70 years after the start of HPV vaccination (population=10 million). (a) QALYs-gained and (b) cost offsets for 2-dose
girls-only vaccination protecting for 10 years, 20 years and 30 years; (c) incremental QALYs-gained and (d) cost offsets of giving the 3rd dose or adding 2-dose boys vaccination
to girls programme. Base-case: vaccination coverage=80%, vaccine-type efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1. Duration of cross-protection is
assumed to be lifelong when vaccine-type duration of protection is lifelong, otherwise duration of cross-protection is assumed to be 10 years. VD: vaccine duration, QALY:
quality-adjusted life-years.
Our results suggest that a two-dose schedule that provides pro-
tection for more than 30 years would likely prevent the majority
of preventable vaccine-type HPV infections and diseases, which
entails that the added value of the third dose would be limited.
This is because, at 30 years duration of protection, two-dose vacci-
nation would confer protection during a signiﬁcant proportion of
the peak years of sexual activity and HPV infection (18–35 years).
Our results also indicate that two-dose girls & boys vaccination is
likely dominated by a three-dose girls-only strategy, because adding
two doses among boys costs twice as much as adding a third dose
among girls. However, because these two strategies result in com-
parable QALYs-gained, the price for boys would need to be reduced
by more than half (60%-90% depending on duration of protection,
and assuming cost for girls ≥$30) to make a two-dose girls & boys
strategy cost-effective vs. three-dose girls-only.
Two key issues must be considered when using these results for
decision-making. First, the policy decisions regarding alternative
HPV vaccine schedules will depend on the evaluation of risks and
uncertainties related to the duration of protection of two and three
doses. Policy-makers could decide that evidence is sufﬁcient for the
implementation of two-dose girls-only vaccination based on the fol-
lowing observations: (i) three doses in young women 16–26 years
of agehas shown sustained efﬁcacy for almost 10 years [39], (ii) two
doses in girls aged 9–13 years have shown noninferior immuno-
genicity compared to three doses in young women aged 16–26
years [14] and (iii) our results indicate that two-dose girls-only vac-
cination is cost-effective if the vaccine protects for longer than 10
years. On the other hand, the duration of vaccine protection with
two doses remains uncertain. Should this duration be less than 20
years, a third dose extending the duration of protection (≥5 years)
would likely produce substantial additional beneﬁts. Second, for
equity reasons, policy-makers’ or society’swillingness to pay for an
additionalQALY-gainedmaybehigher for two-dose girls&boysvac-
cination than a third dose amonggirls-only. Thepotential additional
beneﬁts of the third dose occur among women and heterosexual
men, who would also beneﬁt from a two-dose girls-only strategy.
However, adding boys to an HPV vaccination programme would
extend beneﬁts to MSM, who do not beneﬁt from the herd effects
of girls-only vaccination [55] and have a disproportionately high
burden of HPV-related disease [56,57]. Hence, policy-makers may
deem a two-dose girls & boys strategy worthwhile even though it is
likely to be less cost-effective than a three-dose girls-only strategy.
Toour knowledge, no studyhas examined the cost-effectiveness
of different HPV vaccination schedules. However, a previous
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Fig. 2. Incremental cost-effectiveness of 2- and 3-dose vaccination strategies. (a) Duration of protection 2 doses =10 years & 3 doses =20 years, (b) duration of protection
2 doses =20 years & 3 doses =20 years, (c) duration of protection 2 doses =20 years & 3 doses =25 years, (d) duration of protection 2 doses =20 years & 3 doses = life (e)
duration of protection 2 doses =30 years & 3 doses =35 years, (f) duration of protection 2 doses =30 years & 3 doses = Life. Base-case: vaccination coverage=80%, vaccine-type
efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1; duration of cross-protection is assumed to be lifelong when vaccine-type duration of protection is
lifelong, otherwise duration of cross-protection is assumed to be 10 years. QALY: quality-adjusted life-years; population of 170,000 individuals. Each parameter set was run
50 times. Results are themedian and interquartile range (1st and 3rd quartiles ofmodel simulations). The blue line represents the cost-effectiveness threshold ($40,000/QALY-
gained). All vaccination scenarios include a 5-year 3-dose catch-up campaign. Hence, the cost-effectiveness ratios of 2-dose programmes are slightly inﬂuenced by 3-dose
catch-up vaccine efﬁcacy and duration of protection. The comparator for 3-dose girls & boys vaccination is the most cost-effective strategy between 3-dose girls-only and
2-dose girls & boys, as indicated by the dotted line connecting the vaccination strategies.
comparative modelling analysis, using our model and one from
England [58], examined the potential population-level impact of
two- and three-dose girls-only HPV vaccination. The conclusions
of both models were similar when examining 40–80% vaccination
coverage: the predicted added population-level effectiveness of a
third dose at preventing cervical cancer is minimal if the duration
of protection of two doses is at least 20–30 years.
The results from the comparative analysis and the robustness
of our conclusions to vaccine costs/dose and vaccination cover-
age (between 50–80%; see Fig. 3 and Supplementary Table 3),
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Fig. 3. Sensitivity analysis. Cost-effectiveness of (a) 2-dose girls-only vaccination strategy, (b) 3-dose girls-only and 2-dose girls & boys vaccination strategies vs. 2-dose girls-only (only themost cost-effective strategy is shown), and (c)
3-dose girls & boys vaccination strategy vs. the most cost-effective strategy between 3-dose girls-only and 2-dose girls & boys (the comparator for 3-dose girls & boys vaccination is the strategy shown in c). Base-case: coverage=80%,
vaccine-type efﬁcacy=95%, cross-protective efﬁcacy= see Supplementary Table 1. Sensitivity analysis: in the sensitivity analyses, only the parameters indicated in the description were varied, holding other parameter values
at the base-case level. Max (Min) burden of disease: all costs and QALYs-lost parameters, and % HPV-6/11 in AGW are given their maximum (minimum) values from the literature (Supplementary Table 2). Deﬁnitions. QALY:
quality-adjusted life-years; coverage: vaccination coverage; AGW: anogenital warts; MSM: men-who-have-sex-with-men; RR: relative risk of disease in MSM vs. heterosexual males; ICER: incremental cost-effectiveness ratio.
Each parameter set was run 50 times. Solid dots represent the median, boxes the 1st and 3rd quartiles of model simulations, and the “error-bars” the 10th and 90th percentiles of model simulations.
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suggests that the main cost-effectiveness conclusions of this paper
are likely to be generalisable to other high income countries with
HPV epidemiology, health care costs and cervical screening sim-
ilar to England and Canada. However, our results should not be
extrapolated to resource-poor settings due to differences in sexual
behaviour and HPV epidemiology.
A limitation of our analysis is the validity of data on the pro-
portion of MSM in the population and the burden of disease within
this population. However, even when the proportion of MSM was
assumed to be high (7% vs. 3% in the base-case), vaccinating boys
with two doses remained dominated by three-dose girls-only vac-
cination. A second limitation of the analysis is that our model
assumes no herd-protection from girls-only vaccination to MSM.
Herd-protection to MSM is only included in scenarios with male
vaccination, potentially overestimating the impact of including
boys in vaccination programmes. However, no herd-immunity has
been observed inMSM following the introduction of girls-only HPV
vaccination [59].
As recommended by good modelling practice, we conducted
internal, between-model and external/predictive validation [60].
First, HPV-ADVISEwas calibrated tohighly-stratiﬁedCanadiandata
on sexual behaviour, natural history and cervical cancer screening
(internal validation), and model predictions were performed using
multiple good ﬁtting parameter sets. Secondly, as discussed above,
our two-dose effectiveness predictions are consistent with those
from a model used to inform HPV immunisation decisions in
England (between-model validation) [58]. Finally, our model qual-
itatively reproduces short-term post-vaccination data showing
important and rapid declines in anogenital warts and herd effects
in young heterosexual men from vaccinating girls-only with high
coverage, such as those reported for Australia (external/predictive
validation) [55,59,61] (see Supplementary Fig. 4).
Our cost-effectiveness analysis provides new evidence to help
decision-makers weigh the potential risks and beneﬁts of reducing
HPV vaccination schedules from three to two doses for different
assumptions about duration of protection. Independently of the
schedule implemented, careful long-term surveillance is essential
as duration of protection remains the key uncertainty in the effec-
tiveness of HPV vaccination programmes.
Acknowledgements
We are indebted to Compute Canada for providing us with the
power necessary to run the simulations. We would also like to
acknowledge Dr. Van de Velde (NVDV) who programmed most
components of HPV-ADVISE and helped design the model. Finally,
we thank Drs. Vladimir Gilca, Marie-Hélène Mayrand and Patricia
Goggin for comments on the analysis. Contributors: MB designed
the study, co-drafted the article, had full access to all of the data
in the study, and takes responsibility for the integrity of the data
and the accuracy of the data analysis. JFL, MD, MJ, MCB, TM, PLM,
EF and CS commented on the study design and model structure.
JFL and MD co-drafted the paper. MB, MCB and NVDV designed
HPV-ADVISE. MB and JFL programmed the economic components
of the model. EF provided the data necessary for the analysis. JFL
andMBperformed theanalysis. All authors contributed to the inter-
pretation of results, critically revised the manuscript for important
intellectual content and approved the ﬁnal version submitted for
publication.Conﬂict of interest statement:MB andCShave consulted
and received reimbursement for travel expenses fromMerck Frosst
and GlaxoSmithKline. EF has served as occasional consultant or
advisory board member for Merck and GlaxoSmithKline JFL, MD,
MJ, MCB, TM, and PLM have no conﬂicts of interest to declare.
Funding: This work was supported by the Canada Research Chairs
programme (support for MB), a team grant from the Canadian
Institutes ofHealthResearch (grantno. CRN-83320) and theQuébec
Ministry of Health and Social Services. The funders had no role in
design and conduct of the study; collection, management, analysis,
and interpretation of the data; and preparation, review, or approval
of the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.vaccine.2014.07.099.
References
[1] Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papil-
lomavirus vaccine introduction – the ﬁrst ﬁve years. Vaccine 2012;30(Suppl.
5):F139–48.
[2] Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al.
Epidemiologic classiﬁcation of human papillomavirus types associated with
cervical cancer. N Engl J Med 2003;348(6):518–27.
[3] De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S.
Prevalence and type distribution of human papillomavirus in carcinoma and
intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J
Cancer 2009;124(7):1626–36.
[4] Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human
papillomavirus prevalence in invasive penile cancer. Cancer Causes Control
2009;20(4):449–57.
[5] Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types
in head and neck squamous cell carcinomas worldwide: a systematic review.
Cancer Epidemiol Biomark Prev 2005;14(2):467–75.
[6] Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history
of genital warts: analysis of the placebo arm of 2 randomized phase III trials of
a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect
Dis 2009;199(6):805–14.
[7] Garland SM,Hernandez-AvilaM,Wheeler CM, Perez G, Harper DM, Leodolter S,
et al. Quadrivalent vaccine against humanpapillomavirus toprevent anogenital
diseases. N Engl J Med 2007;356(19):1928–43.
[8] Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV,
et al. Population-level impact of the bivalent, quadrivalent, and nonavalent
human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst
2012;104(22):1712–23.
[9] Brisson M, Van de Velde N, Boily MC. Economic evaluation of human
papillomavirus vaccination in developed countries. Public Health Genomics
2009;12(5–6):343–51.
[10] Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention
in developed countries. Vaccine 2008;26(Suppl. 10):K76–86.
[11] Canfell K, ChessonH,KulasingamSL, Berkhof J, DiazM,Kim JJ.Modelingpreven-
tative strategies against human papillomavirus-related disease in developed
countries. Vaccine 2012;30(Suppl. 5):F157–67.
[12] BC Center for Disease Control. Immunization in British Colombia; 2008.
Available from: http://www.bccdc.ca/NR/rdonlyres/4F2E7994-8A4A-4F2E-
9E3E-FFFB7BAD0B1E/0/2008AnnualReportFINALcolour28OCT2010.pdf
[accessed June 2013].
[13] Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M,
et al. Proof-of-principle evaluation of the efﬁcacy of fewer than three doses of
a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103(19):1444–51.
[14] Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immuno-
genicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young
women: a randomized clinical trial. JAMA 2013;309(17):1793–802.
[15] Kahn JA, Bernstein DI. HPV vaccination: too soon for 2 doses? JAMA
2013;309(17):1832–4.
[16] Jit M, BrissonM.Modelling the epidemiology of infectious diseases for decision
analysis: a primer. Pharmacoeconomics 2011;29(5):371–86.
[17] Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions
of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine
2010;28(33):5473–84.
[18] Brisson M, Van de Velde N, Drolet M, Boily MC, Franco EL, Mayrand
MH, et al. HPV-advise: technical appendix. J Natl Cancer Inst 2012,
http://dx.doi.org/10.1093/jnci/djs395. http://www.marc-brisson.net/
HPVadvise.pdf
[19] Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J,
et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Mod-
eling Good Research Practices Task Force Working Group-5. Med Decis Mak
2012;32(5):712–21.
[20] WHO. Investing inhealth for economicdevelopment. Report of theCommission
on Macroeconomics and Health, Geneva, Switzerland; 2001.
[21] WHO. WHO-CHOICE. World Health Organization statistical information sys-
tem: choosing interventions that are cost effective; 2006.
[22] Department of Health UK, Public Health England. HPV vaccination
programme: HPV annual survey 2011–2012; 2012. Available from:
J.-F. Laprise et al. / Vaccine 32 (2014) 5845–5853 5853
https://www.gov.uk/government/uploads/system/uploads/attachment data/
ﬁle/244479/HPV AnnualVaccineUptake2011-2012.pdf [accessed 30.10.13].
[23] Department of Health Australian Government. Immunise Australia Program:
human papillomavirus (HPV); 2013. Available from: http://www.health.gov.
au/internet/immunise/publishing.nsf/Content/immunise-hpv [accessed
30.10.13].
[24] Ministère de la Santé et des Services Sociaux du Québec (MSSS). Vigie – Inter-
ventions: Couverture vaccinale en milieu scolaire. Flash Vigie: Bull qué vigie
d’interv mal infect 2010;5(3):1–2.
[25] Drolet M, Brisson M, Maunsell E, Franco EL, Coutlée F, Ferenczy A, et al. The
psychosocial impact of an abnormal cervical smear result. Psychooncology
2012;21(10):1071–81.
[26] Drolet M, Brisson M, Maunsell E, Franco EL, Coutlée F, Ferenczy A, et al. The
impact of anogenitalwarts onhealth-relatedquality of life: a 6-monthprospec-
tive study. Sex Transm Dis 2011;38(10):949–56.
[27] Statistics CanadaCanadianCommunityHealth Survey (CCHS–Cycle 3.1); 2005.
Available from: www.statcan.gc.ca [accessed January 2011].
[28] Demers A, Kliewer EV, Musto G, Butler J, Elliot L, Shearer B, et al. Epidemiol-
ogy of cervical abnormalities and utilization of related health care resources.
Winnipeg: Cancer Care Manitoba; 2009.
[29] Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, et al.
Selected class I and class II HLA alleles and haplotypes and risk of high-grade
cervical intraepithelial neoplasia. Int J Cancer 2008;122(12):2820–6.
[30] Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A,
et al. The natural history of type-speciﬁc human papillomavirus infections
in female university students. Cancer Epidemiol Biomark Prev 2003;12(6):
485–90.
[31] Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S,
et al. Randomized controlled trial of human papillomavirus testing versus Pap
cytology in the primary screening for cervical cancer precursors: design, meth-
ods and preliminary accrual results of the Canadian cervical cancer screening
trial (CCCaST). Int J Cancer 2006;119(3):615–23.
[32] Coutlee F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, et al.
Distribution of human papillomavirus genotypes in cervical intraepithelial
neoplasia and invasive cervical cancer in Canada. J Med Virol 2011;83(6):
1034–41.
[33] Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papil-
lomavirus type distribution in 30,848 invasive cervical cancers worldwide:
variation by geographical region, histological type and year of publication. Int
J Cancer 2011;128(4):927–35.
[34] Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing
patterns in incidence and mortality. Int J Gynecol Cancer 2001;11(1):24–31.
[35] Public Health Agency of Canada. Cancer surveillance on-line. Available from:
http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cancer/index-eng.php [accessed
January 2011].
[36] BCCancerAgency. Cervical cancer screeningprogram. 2009annual report, Van-
couver, BC;2009.Available from:http://www.bccancer.bc.ca [accessed January
2011].
[37] Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-
year trends in the incidence and prevalence of diagnosed anogenital warts in
Canada. Sex Transm Dis 2009;36(6):380–6.
[38] Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective
efﬁcacy of two human papillomavirus vaccines: a systematic review andmeta-
analysis. Lancet Infect Dis 2012;12(10):781–9.
[39] Naud P. Sustained immunogenicity and efﬁcacy of the HPV-16/18 vaccine in
women aged 15–25 years: follow-up to 9.4 years. In: Abstract presented at the
27th International Papillomavirus Conference and Clinical Workshop. 2011. p.
17–21.
[40] Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost–utility
analyses: usingnationalmeasures to create condition-speciﬁc values.MedCare
1998;36(6):778–92.
[41] InstituteofMedicineof theNationalAcademies.Vaccines for the21st century: a
tool for decision making; 1999. Available from: http://www.iom.edu/Reports/
1999/Vaccines-for-the-21st-Century-A-Tool-for-Decisionmaking.aspx
[42] Rogers SN,Miller RD, Ali K,MinhasAB,WilliamsHF, LoweD. Patients’ perceived
health status following primary surgery for oral and oropharyngeal cancer. Int
J Oral Maxillofac Surg 2006;35(10):913–9.
[43] Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-
effectiveness of prophylactic human papillomavirus vaccines in Canada.
Vaccine 2007;25(29):5399–408.
[44] Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A
cost–utility analysis of cervical cancer vaccination in preadolescent Canadian
females. BMC Public Health 2009;9:401.
[45] Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P. Cost-
effectiveness of high-risk human papillomavirus testing for cervical cancer
screening in Quebec: Canada. Can J Public Health 2010;101(3):220–5.
[46] Kulasingam SL, Rajan R, St Pierre Y, Atwood CV, Myers ER, Franco EL. Human
papillomavirus testingwithPap triage for cervical cancerprevention inCanada:
a cost-effectiveness analysis. BMC Med 2009;7:69.
[47] Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs asso-
ciated with genital warts in Canada. Sex Transm Infect 2009;85(2):111–5.
[48] Benedet JL, BertrandMA,Matisic JM, Garner D. Costs of colposcopy services and
their impact on the incidence and mortality rate of cervical cancer in Canada. J
Low Genit Tract Dis 2005;9(3):160–6.
[49] Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The
cost-effectiveness of male HPV vaccination in the United States. Vaccine
2011;29(46):8443–50.
[50] Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the
United States. Vaccine 2010;28(42):6858–67.
[51] Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus
vaccination in the United Kingdom. BMJ 2008;337:a769.
[52] Olsen J, JepsenMR. Human papillomavirus transmission and cost-effectiveness
of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess
Health Care 2010;26(2):183–91.
[53] Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vac-
cination programs. Emerg Infect Dis 2004;10(11):1915–23.
[54] Comité sur l’immunisation du Québec (CIQ) et Comité scientiﬁque ad hoc VPH.
La Vaccination contre les VPH au Québec: Mise à jour des connaissances et
propositions du comité d’experts. Direction des risques biologiques et de la
santé au travail. Institut national de santé publique Québec (INSPQ); 2012.
[55] Ali H, Donovan B,WandH, Read TR, ReganDG, Grulich AE, et al. Genitalwarts in
young Australians ﬁve years into national human papillomavirus vaccination
programme: national surveillance data. BMJ 2013;346:f2032.
[56] Palefsky JM.Humanpapillomavirus-related disease inmen: not just awomen’s
issue. J Adolesc Health 2010;46(4 Suppl.):S12–9.
[57] Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine
2006;24(Suppl. 3):S3.11–25.
[58] JitM, Choi YH, Laprise JF, DroletM, BoilyMC, BrissonM. Two-dose strategies for
human papillomavirus vaccination: how well do they need to protect? Vaccine
2014;32(26):3237–42.
[59] Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near
disappearance of genital warts in young women 4 years after commencing
a national human papillomavirus (HPV) vaccination programme. Sex Transm
Infect 2011;87(7):544–7.
[60] Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C,
et al. Principles of good practice for decision analytic modeling in health-care
evaluation: report of the ISPOR Task Force on Good Research Practices – mod-
eling studies. Value Health 2003;6(1):9–17.
[61] Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadri-
valent human papillomavirus vaccination and trends in genital warts in
Australia: analysis of national sentinel surveillance data. Lancet Infect Dis
2011;11(1):39–44.
